Boobalan Pachaiyappan's Stock Ratings

Roth Capital Analyst

Boobalan Pachaiyappan is an analyst at Roth Capital. Analyst ratings are quantitative and qualitative analysis of a stock by Wall Street stock rating analysts. Stock ratings consist of expected future growth, current stock valuation and macroeconomic trends. Updated 12/15/2025

Updated: Dec 15, 2025

Overall Average Return

60.3%

Smart Score

74.7%

Overall Average Return Percentile

95th

Number of Ratings

26
Buy NowGet Alert
12/11/2025OVIDBuy Now
Ovid Therapeutics
$1.5791.08% → $3Initiates → BuyGet Alert
11/19/2025CINGBuy Now
Cingulate
$4.10290.09%$17 → $16MaintainsBuyGet Alert
11/13/2025PYPDBuy Now
PolyPid
$4.00125%$10 → $9MaintainsBuyGet Alert
11/12/2025CAPRBuy Now
Capricor Therapeutics
$26.59-51.1%$12 → $13MaintainsBuyGet Alert
10/15/2025CINGBuy Now
Cingulate
$4.10314.47%$10 → $17MaintainsBuyGet Alert
09/17/2025RNABuy Now
Avidity Biosciences
$71.89-13.76% → $62Initiates → BuyGet Alert
08/18/2025RVPHBuy Now
Reviva Pharmaceuticals
$0.66357.6%$7 → $3ReiteratesBuy → BuyGet Alert
08/15/2025LGVNBuy Now
Longeveron
$0.58417.06%$10 → $3MaintainsBuyGet Alert
08/13/2025GANXBuy Now
Gain Therapeutics
$4.0647.78%$7 → $6MaintainsBuyGet Alert
08/12/2025CRVOBuy Now
CervoMed
$8.3092.77%$20 → $16ReiteratesBuy → BuyGet Alert
07/14/2025CAPRBuy Now
Capricor Therapeutics
$26.59-54.86%$31 → $12MaintainsBuyGet Alert
06/18/2025VRNABuy Now
Verona Pharma
——$92 → $116ReiteratesBuy → BuyGet Alert
06/18/2025PYPDBuy Now
PolyPid
$4.00125%$12 → $9MaintainsBuyGet Alert
06/17/2025CAPRBuy Now
Capricor Therapeutics
$26.5916.61%$31 → $31ReiteratesBuy → BuyGet Alert
06/05/2025PYPDBuy Now
PolyPid
$4.00125% → $9Initiates → BuyGet Alert
05/19/2025CINGBuy Now
Cingulate
$4.10168.19%$12 → $11MaintainsBuyGet Alert
03/18/2025CRVOBuy Now
CervoMed
$8.30140.96%$15 → $20MaintainsBuyGet Alert
03/11/2025CRVOBuy Now
CervoMed
$8.3080.72%$7 → $15MaintainsBuyGet Alert
01/10/2025VRNABuy Now
Verona Pharma
—— → $68Initiates → BuyGet Alert
01/10/2025RVPHBuy Now
Reviva Pharmaceuticals
$0.66967.72% → $7Initiates → BuyGet Alert
01/10/2025CINGBuy Now
Cingulate
$4.10192.57% → $12Initiates → BuyGet Alert
12/24/2024GANXBuy Now
Gain Therapeutics
$4.0672.41%$7 → $7MaintainsBuyGet Alert
12/05/2024CRVOBuy Now
CervoMed
$8.30442.17% → $45Initiates → BuyGet Alert
12/05/2024TRDABuy Now
Entrada Therapeutics
$11.32156.18% → $29Initiates → BuyGet Alert
12/05/2024GANXBuy Now
Gain Therapeutics
$4.0672.41% → $7Initiates → BuyGet Alert
12/05/2024LGVNBuy Now
Longeveron
$0.581623.54% → $10Initiates → BuyGet Alert

Recent Analyst Stock Rating News

Oracle To Rally More Than 20%? Here Are 10 Top Analyst Forecasts For Wednesday
Oracle To Rally More Than 20%? Here Are 10 Top Analyst Forecasts For Wednesday
This Excelerate Energy Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
This Excelerate Energy Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
Aclaris Therapeutics' ATI-1777 Faces Uphill Battle In Atopic Dermatitis Treatment Landscape, Analyst Downgrades
Aclaris Therapeutics' ATI-1777 Faces Uphill Battle In Atopic Dermatitis Treatment Landscape, Analyst Downgrades
HC Wainwright downgrades Aclaris Therapeutics post Phase 2b results of ATI-1777 for atopic dermatitis. Analyzing efficacy, commercial prospects, and competitive landscape.
Substance Use Disorder Focused Anebulo Could Be Attractive Acquisition Target, Analyst Says
Substance Use Disorder Focused Anebulo Could Be Attractive Acquisition Target, Analyst Says
H.C.
The Best Trading Research Platform
For Retail Investors and Professional Trades Alike.
Get Started for Free
Connect With Us
instagramlinkedinyoutubeblueskymastodon
About Benzinga
Market Resources
Trading Tools & Education
Ring the Bell
© 2025 Benzinga | All Rights Reserved